BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Abingworth Wins European Venture Capital Journal Award


2/4/2008 11:35:18 AM

London, UK, 31st January 2008 - Abingworth, the international life sciences investment group, today announced that it has been named “House of the Year – Life Sciences” 2007 at the European Venture Capital Journal annual awards for the second consecutive year. The award, which was presented by RT Hon. William Hague MP, is in recognition of Abingworth’s achievements over the past 12 months.

The award follows Abingworth’s success in 2007 which started off with Abingworth closing its £300 million ($587 million) life sciences fund, Abingworth Bioventures V LP (ABV V) in January 2007. This is Abingworth’s 8th life sciences fund and the largest venture fund dedicated to life sciences raised by a firm based in Europe.

During the year Abingworth participated in 8 financings, including the European companies: Novexel (France; developing novel antibacterials and anti-fungals), Prosensa (Netherlands; focused on RNA interference therapeutics using exon skipping technology) and more recently Syntaxin (UK; developing novel biologic drugs that control cell secretion).

Dr Stephen Bunting, Managing Partner at Abingworth said: “We are very pleased to receive this recognition, the second year running. 2007 started well for us with the closure of our fund, Abingworth Bioventures V, which was closed in less than 3 months. Later we successfully completed Ablynx IPO on Euronext Brussels, which testifies that European markets are more than capable of supporting growing life science companies.”

This year’s nominees in the VC House of the Year – Life Sciences category were Atlas Venture, GIMV, Imperial Innovations, Life Science Partners, and Sofinnova Partners.

Background

Abingworth is an international life sciences investment group active on both sides of the Atlantic with offices in London, Cambridge (UK), Menlo Park (California) and Boston. Founded in 1973, the company invests across all stages of development, including early-stage as well as public companies. Abingworth has funds under management of over $1.25 billion.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES